Hybrids from farnesylthiosalicylic acid and hydroxamic acid as dual ras-related signaling and histone deacetylase (HDAC) inhibitors: Design, synthesis and biological evaluation

ChemMedChem

Volumn 10, Issue 6, 2015, Pages 971-976

  Ling, Yong ^a,b   Wang, Xuemin ^a   Wang, Chenniu ^a   Xu, Chenjun ^a   Zhang, Wei ^a   Zhang, Yihua ^a,b   Zhang, Yanan ^a  

^a NANTONG UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

antitumor agents; farnesylthiosalicylic acids; histone deacetylases; hydroxamic acids; ras related signaling pathways

Indexed keywords

ANTINEOPLASTIC AGENT; HISTONE DEACETYLASE INHIBITOR; HYDROLASE INHIBITOR; HYDROXAMIC ACID; N [ 4 (HYDROXYAMINO) 4 OXOBUTYL] 2 [( 3,7,11 TRIMETHYLDODECA 2,6, 10 TRIEN 1 YL)THIO]BENZAMIDE; RAS PROTEIN; SALIRASIB; UNCLASSIFIED DRUG; VORINOSTAT; FARNESOL; SALICYLIC ACID DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BLADDER CARCINOMA; BREAST CANCER; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; COLUMN CHROMATOGRAPHY; COMPARATIVE STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IC50; IN VITRO STUDY; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TUMOR RECURRENCE; ANALOGS AND DERIVATIVES; CELL LINE; CHEMISTRY; PRECLINICAL STUDY;

CELL LINE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; FARNESOL; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; SALICYLATES;

EID: 84930686121     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201500019     Document Type: Article

References (28)

1. S. Gysin, M. Salt, A. Young, F. McCormick, Genes Cancer 2011, 2, 359.
2. S. Eser, A. Schnieke, G. Schneider, D. Saur, Br. J. Cancer 2014, 111, 817.
3. Y. Pylayeva-Gupta, E. Grabocka, D. Bar-Sagi, Nat. Rev. Cancer 2011, 11, 761.
4. M. Paolo, S. Assunta, R. Antonio, S. P. Claudia, B. M. Anna, S. Clorinda, C. Francesca, C. Fortunato, G. Cesare, Rev. Recent Clin. Trials 2013, 8, 93.
5. A. M. Tsimberidou, M. A. Rudek, D. Hong, C. S. Ng, J. Blair, H. Goldsweig, R. Kurzrock, Cancer Chemother. Pharmacol. 2010, 65, 235.
6. A. Biran, M. Brownstein, R. Haklai, Y. Kloog, Int. J. Cancer 2011, 128, 691.
7. G. Ding, H. D. Liu, Q. Huang, H. X. Liang, Z. H. Ding, Z. J. Liao, G. Huang, FEBS Lett. 2013, 587, 880.
8. J. S. Carew, F. J. Giles, S. T. Nawrocki, Cancer Lett. 2008, 269, 7.
9. M. Haberland, R. L. Montgomery, E. N. Olson, Nat. Rev. Genet. 2009, 10, 32.
10. A. Hayashi, A. Horiuchi, N. Kikuchi, T. Hayashi, C. Fuseya, A. Suzuki, I. Konishi, T. Shiozawa, Int. J. Cancer 2010, 127, 1332.
11. J. E. Bolden, M. J. Peart, R. W. Johnstone, Nat. Rev. Drug Discovery 2006, 5, 769.
12. S. Grant, C. Easley, P. Kirkpatrick, Nat. Rev. Drug Discovery 2007, 6, 21.
13. R. Frye, M. Myers, K. C. Axelrod, E. A. Ness, R. L. Piekarz, S. E. Bates, S. Booher, Clin. J. Oncol. Nurs. 2012, 16, 195.
14. C. A. Thompson, Am. J. Health-Syst. Pharm. 2014, 71, 1328.
15. S. Fouliard, R. Robert, A. Jacquet-Bescond, Q. C. du Rieu, S. Balasubramanian, D. Loury, Y. Loriot, A. Hollebecque, I. Kloos, J. C. Soria, M. Chenel, S. Depil, Eur. J. Cancer 2013, 49, 2791.
16. A. T. Brunetto, J. E. Ang, R. Lal, D. Olmos, L. R. Molife, R. Kristeleit, A. Parker, I. Casamayor, M. Olaleye, A. Mais, B. Hauns, V. Strobel, B. Hentsch, J. S. de Bono, Clin. Cancer Res. 2013, 19, 5494.
17. A. Furlan, V. Monzani, L. L. Reznikov, F. Leoni, G. Fossati, D. Modena, P. Mascagni, C. A. Dinarello, Mol. Med. 2011, 17, 353.
18. M. P. Morelli, J. J. Tentler, G. N. Kulikowski, A. C. Tan, E. L. Bradshaw-Pierce, T. M. Pitts, A. M. Brown, S. Nallapareddy, J. J. Arcaroli, N. J. Serkova, M. Hidalgo, F. Ciardiello, S. G. Eckhardt, Clin. Cancer Res. 2012, 18, 1051.
19. A. Morotti, D. Cilloni, F. Messa, F. Arruga, I. Defilippi, S. Carturan, R. Catalano, V. Rosso, A. Chiarenza, C. Pilatrino, A. Guerrasio, R. Taulli, E. Bracco, M. Pautasso, D. Baraban, E. Gottardi, G. Saglio, Cancer 2006, 106, 1188.
20. A. Quintas-Cardama, J. Cortes, Blood 2009, 113, 1619.
21. L. Zhang, Y. Han, Q. Jiang, C. Wang, X. Chen, X. Li, F. Xu, Y. Jiang, Q. Wang, W. Xu, Med. Res. Rev. 2015, 35, 63.
22. S. Mahboobi, A. Sellmer, M. Winkler, E. Eichhorn, H. Pongratz, T. Ciossek, T. Baer, T. Maier, T. Beckers, J. Med. Chem. 2010, 53, 8546.
23. C. J. Lai, R. Bao, X. Tao, J. Wang, R. Atoyan, H. Qu, D. G. Wang, L. Yin, M. Samson, J. Forrester, B. Zifcak, G. X. Xu, S. DellaRocca, H. X. Zhai, X. Cai, W. E. Munger, M. Keegan, C. V. Pepicelli, C. Qian, Cancer Res. 2010, 70, 3647.
24. L. Han, L. Wang, X. Hou, H. Fu, W. Song, W. Tang, H. Fang, Bioorg. Med. Chem. 2014, 22, 1529.
25. Y. Ling, Z. Wang, H. Zhu, X. Wang, W. Zhang, L. Chen, Z. Huang, Y. Zhang, Bioorg. Med. Chem. 2014, 22, 374.
26. S. C. Mwakwari, W. Guerrant, V. Patil, S. I. Khan, B. L. Tekwani, Z. A. Gurard-Levin, M. Mrksich, A. K. Oyelere, J. Med. Chem. 2010, 53, 6100.
27. A. Laurenzana, M. Balliu, C. Cellai, M. N. Romanelli, F. Paoletti, PLoS One 2013, 8, e 58267.
28. C. C. Yu, S. L. Pan, S. W. Chao, S. P. Liu, J. L. Hsu, Y. C. Yang, T. K. Li, W. J. Huang, J. H. Guh, Biochem. Pharmacol. 2014, 90, 320.